leadf
logo-loader
viewImmuPharma PLC

Immupharma PLC - Lupuzor Pivotal Phase III Study Update

RNS Number : 6822I
Immupharma PLC
23 March 2018
 

                                                                                                                                                                      23 March 2018

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

Lupuzor™ Pivotal Phase III Study Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces  that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor™ is the Company's lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, Chairman, said: "With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

 

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

 

Northland Capital Partners Limited

David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

 

 

                                                  

+44 (0)20 3861 6625

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBDDCBKDNNB

Quick facts: ImmuPharma PLC

Follow
AIM:IMM

Price: 7.5

Market Cap: £18.77 m

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s CEO, Tim McCarthy, presents commercial strategy for lupus drug...

ImmuPharma PLC (AIM:IMM)'s (LON:IMM) CEO, Tim McCarthy, presents commercial strategy for lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months.  The study...

on 17/8/21

2 min read